Experience matters when it improves the decision at hand.
S&P combines medical, scientific, commercial, and entrepreneurial experience across pharma, biotech, medtech, and selected digital health situations. Our work ranges from advisory and project leadership to operational interim responsibility.
Our experience covers the following twelve medical and technology domains. The graphic records the fields included in our source presentation for analysis, consulting and project services.
Expertise in Indication & Technology FieldsGraphic in English. Enlarge to read the detail; use Back to page to return.
DIC / Multiple Organ Failure acc. to Septicemia, Polytrauma, Burns, Cancers,
Re-Occlusion after coronary artery bypass grafting (CABG )
Percutaneous transluminal angioplasty and coronary angioplasty (PTA/PTCA)
Re-Occlusion after thrombolysis in acute myocardial infarction-prevention,
Peripheral arterial Bypass - Prevention of Re-occlusion
Deep Vein Thrombosis of patients with high risks such as Hip Surgery and major abdominal Surgery Pulmonary Embolism
Heparin-induced Thrombocytopenia
Thombosis in Patients undergoing dialysis
Biotechnology
Biopharmaceuticals
Biomarkers
Biosimilars
Genomics
Proteomics
Molecular Biology
Biochemical Processes
Industrial Separations
DNA Profiling For Forensics & Paternity Testing
Woundcare
VAC-Woundhealing
Decubital Ulcers/ Diabetic Ulcers / Ulcera Cruris
Hemorrhoides
Infection / Diseases
Mycotic Diseases
Hepatitis B and C
Bacterial
Viral Diseases
HIV
Flu
Dermatology / Allergology
Psoriasis
Ekcemas
Allergies/Asthma
Cutaneous Infections (mycotic, bacterial)
Diagnostics
Laboratory Testing
Isotopes / Scintigraphy
Plasma-Levels etc.
RAID’s
Ultra-Sound / X-Ray
Tumor Markers
CNS-Diseases
Epilepsy
Depression / Anxiety / Insomnia
Parkinson’s Disease
Schizophrenia
Alzheimers Disease
Multiple Sclerosis
Alcohol Disease
Pulmonary Diseases
COPD (Chron. Obstr. Pulm. Dis.)
RDS (Resp. Distr. Syndr.)
Asthma
Shock Lung
Pulmonary Hypertension
Anesthesiology / Pain / Rheumatoid Diseases
Opioids & Non-Opioids
Patches
Devices / Catheterizations
NSAID‘s
CoX-II-Inh.
Selected client projects / Projects A–D
Market entry, technology and product strategy
Projects A–D illustrate European market assessments, technology assessment and product-related strategy in biotechnology and pharmaceuticals.
Selected Client Projects - 1Graphic in English. Enlarge to read the detail; use Back to page to return.
Selected historical assignments, anonymized. The examples describe project settings, objectives, contributions and scope, not additional or guaranteed business outcomes.
Read the original project details
Client A / Biotech
Project setting
European Market Assessment with the scope:
Expanding the own Business into EU
Special Focus on HIV and specific Oncology Indications (own assets in R&D)
Project objectives
Determination of Market Potential in the targeted Key Indications
Evaluation of conditions re. Building of an own Representation vs. Alliances
Key deliverables
Definition of Key Assumptions for Business Expansion from the US into the EU Markets
Specific Benchmarks /Country
Strategic Plan: Options for Expansion
Level / countries
G5: France, Germany, Italy, Spain, UK
Level: Corporate for Europe
Client B / Biotech
Project setting
European Market Assessment with the scope:
Expanding the own Business into EU
Special Focus on HIV and Hepatitis B (own assets in R&D)
Project objectives
Determination of Market Potential in the targeted Key Indications
Evaluation of conditions re. Building of an own Representation vs. Alliances
Key deliverables
Definition of Key Assumptions for Business Expansion from the US into the EU Markets
Specific Benchmarks /Country
Strategic Plan: Options for Expansion
Level / countries
G5: France, Germany, Italy, Spain, UK
Level: Corporate for Europe
Client C / Pharmaceutical
Project setting
Existing Franchise Analgesics, however lack of Innovation and aging Portfolio
Need to provide new Assets (e.g. Galenic Line Extentions, Device driven Applicators, NME’s) to M&S
Technology Assessment in Analgesia / Anti-Inflammatory
Identify Companies with strategic Fit for Acquisitions
Key deliverables
Technology Map
Prioritization of Technologies and / or individual Projects / Products
Prioritization of potential Acquisition / Partnering / LicensingCompanies
Level / countries
G 10
Level: Corporate for Global
Client D / Pharmaceutical
Project setting
New, innovative oral antidiabetic Drug in R&D (Phase IIIa)
No previous own Segment Expertise
Detailed Market Assessment
Technology Assessment including direct competition (current and future)
CPA - Customer Perception Audit
Project objectives
Facilitate Project Team (M&S) to gain in depth Under-standing re. Market and Competitive Environment
Assessment of the Potential of the own Project
Analysis of Price-Benchmarks
Key deliverables
Valid Project Strategy
Value Map and Key Benchmarks for Positioning and Differentiations
Business Plan including different Scenarios re. Marketing, Forecasts / Profit
Level / countries
Germany
Level: Affiliate for Germany
Selected client projects / Projects E–H
Development, international planning and portfolio
Projects E–H connect development project management with international strategy, planning and portfolio assignments.
Selected Client Projects - 2Graphic in English. Enlarge to read the detail; use Back to page to return.
Selected historical assignments, anonymized. The examples describe project settings, objectives, contributions and scope, not additional or guaranteed business outcomes.
Read the original project details
Client E / Pharmaceutical
Project setting
Inlicensed oral antidiabetic Drug in R&D (phase I /IIa)
No previous own Development finalized in this Segment
Significant Shortage of own Human Resource to manage the Project
Project objectives
Project Management
Support of specific Functional Areas
Facilitation of Exchange and Interaction with Licensing Partners
Key deliverables
Optimization of Development Process
Continuous In-Process Controlling, Benchmarking and rigorous Go / No-Go Assessments
Level / countries
International Drug Development and Approvals
Market Focus: USA
Level: Corporate for Global
Client F / Pharmaceutical
Project setting
14 Global Development Projects (phase I - IIIb)
International Development Teams
Optimizing interaction between R, D, M&S, HE&P, F&C, Patent Lawyers and Reg.A.
Optimization of Interaction with Partners
Project objectives
Implementation of LifeCycle Management Process
Validation of Global Development Plans
Validation of Global Commercial Plans
Validation of LifeCycle Plans
Key deliverables
Optimization of Benchmark Settings, Processing and Decision Making
Change Management (Resource Allocation)
Prioritization / Cancellation of Development Projects
Level / countries
Development G10
USA
Belgium
Level: Corporate for Global
Client G / Pharmaceutical
Project setting
Strategic Planning Process in Key-Markets
Need to implement Planning Guidelines to harmonize national Planning Approaches
Global summary of national Plans coordinating corporate Functions
Project objectives
Provision of Affiliate Planning Manuals and Planning Tools
Facilitation of Planning Process in the Affiliates
Challenge and Validation of Affiliate Planning
Consolidation of “Global” Plan
Key deliverables
Global Strategic Plans
Comparative Analysis and Decision of clear Action Plans
Trade-Offs re. Investments vs. Market Shares / Revenues vs. Break Evens and local / international Profitability
Level / countries
10 Key Markets: Australia, Brazil, France, Germany, Italy, Spain, Sweden, UK, USA, Japan
Level: Corporate for Global
Client H / Pharmaceutical
Project setting
Business Unit Structure with Diversified Global Portfolio
Need to implement Process identifying Projects/Products with relevance as Global Strategic, Local Strategic and Local Non-Strategic
Need for Resource Allocation Optimizat.
Project objectives
Implement Global Planning Process, following a Dual Approach (Top-Down Corporate / Bottom-Up Affiliate)
Facilitate Process / Challenge and Validation of all Planning
Key deliverables
Global Strategic Plans
Portfolio-Optimization and focus of Resources on Key-Assets
Action Plans, corresponding with Strategic Plans
Trade-Offs re. Investments vs. international Profitability
Level / countries
9 Key Markets: Brazil, Canada, France, Germany, Italy, Spain, UK, USA, Japan
Level: Corporate for Global
Selected client projects / Projects I–J
Company assessment and executive delivery
Projects I–J range from an exit assessment to investment planning and operational executive responsibility in medical technology.
Selected Client Projects - 3Graphic in English. Enlarge to read the detail; use Back to page to return.
Selected historical assignments, anonymized. The examples describe project settings, objectives, contributions and scope, not additional or guaranteed business outcomes.
Read the original project details
Client I / Laboratory & Candidate Screening & Production
Project setting
Evaluate and prioritize the current Technology
Evaluate and prioritize the Innovation Power of R&D-Portfolio
Evaluate the Team Capabilities
Project objectives
Provide Lead Investors with an Exit Rationale (Assess an Exit Potential for a Take Over by an International Group)
Define Upsides and Downsides
conduct a valid SWOT Analysis
Key deliverables
Clear Go-Assessment for an Exit, targeted to the Key Investors
Demonstration of “Taking Care” re. Due Diligence and Guarantee Issues
Convincing the Client Team
Level / countries
International Drug Development and Approvals
Market Focus: Germany, EU, wuith focus on the USA
Client J / Medical Technology (E-Health / Telemedicine
Project setting
Evaluate and prioritize the current Technology
Evaluate and prioritize the Innovation Power of R&D-Portfolio and further Needs
Project objectives
Validation of Global Development Plan
Validation of Global Commercial Plan
Validation of LifeCycle Plan
Evaluate the Team Capabilities to perform adequate IT issues
Evaluate Outsourcing Opportunities
Evaluate Supply Chain Optimization
Evaluate Market Potentials, also by demontraging Medical Needs
Evaluate further Investment Ratios by previous Key Investors
Key deliverables
Implementation of LifeCycle Management Process
Production of advances Business Plan /(Development, Manufacturing, Market Supply, Portfolio Spread, Resource Allocation)
Provision of corresponding Investment Frame, in order to finance either until own commercial Break Even or until Exit.
After Consulting:
Taking Over Function as CEO and CFO (2010 to 2013)
Followed by Vice President Business Development and Strategy
Level / countries
Germany
EU
Eastern Europe
Arabs
USA
Development G10
USA
Experience
Evidence without a logo collection
Public cases are anonymized and structured by decision situation. Client names, brands, logos, metrics, and quotations appear only with documented approval. Confidential reference conversations can be arranged for appropriate assignments.
Proposed case types. Launch readiness, portfolio prioritization, ICCBA and commercial performance, organization and process design, interim executive mandate, and partnering or transaction.
